Axsome's AUVELITY Receives FDA Approval for Alzheimer's Agitation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy AXSM?
Source: NASDAQ.COM
Axsome Therapeutics' stock surged by 14.16% as it reached a 52-week high following the FDA approval of AUVELITY for treating agitation in Alzheimer's disease.
The FDA approval of AUVELITY marks a significant breakthrough for over 7 million patients in the U.S., providing a new treatment option for a critical unmet medical need. This approval is supported by pivotal clinical trials, including ADVANCE-1, which demonstrated AUVELITY's efficacy in improving agitation symptoms. Additionally, Axsome has launched the Auvelity OnMySide™ patient support program to enhance market competitiveness.
This approval not only strengthens Axsome's position in the Alzheimer's treatment market but also reflects the company's commitment to addressing significant patient needs, potentially leading to increased revenue and market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXSM
Wall Street analysts forecast AXSM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 206.530
Low
153.00
Averages
209.54
High
260.00
Current: 206.530
Low
153.00
Averages
209.54
High
260.00
About AXSM
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GameStop Proposes $55.5 Billion eBay Acquisition, Shares Surge
- Acquisition Proposal Surge: GameStop's unsolicited offer to acquire eBay for approximately $55.5 billion has led to a nearly 9% premarket surge in eBay's shares, indicating strong market enthusiasm for a potential merger that could create a formidable competitor to Amazon.
- Setbacks and Expectations Gap: Norwegian Cruise Line reported first-quarter earnings of 23 cents per share and $2.33 billion in revenue, both falling short of analyst expectations, resulting in a 5.5% drop in stock price, reflecting operational challenges amid rising fuel costs.
- Photonics Technology Outlook: Shares of Lumentum and Coherent rose by 3% after Rothschild & Co Redburn initiated buy ratings on both companies, with expectations that the demand for optical content in AI data center networking will drive their stock prices higher.
- Strong Food Sector Performance: Tyson Foods saw its shares rise over 2.5% after reporting better-than-expected fiscal second-quarter results, with adjusted earnings of 87 cents per share and revenue of $13.65 billion, demonstrating the company's resilience in a competitive market.
See More
Axsome Therapeutics Q1 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Performance: Axsome Therapeutics reported a Q1 GAAP EPS of -$1.26, missing expectations by $0.36, indicating ongoing challenges in achieving profitability.
- Revenue Growth: The total net product revenue for Q1 reached $191.2 million, reflecting a 57.4% year-over-year increase and exceeding expectations by $0.51 million, showcasing strong market demand.
- AUVELITY Sales: AUVELITY generated net product revenue of $153.2 million, representing a 59% year-over-year growth, indicating increasing market acceptance for treating agitation associated with Alzheimer's disease.
- Cash Flow Outlook: Axsome believes its current cash is sufficient to fund operations until reaching cash flow positivity, demonstrating confidence in its future financial health.
See More
AXSOME THERAPEUTICS INC: NEEDHAM INCREASES TARGET PRICE FROM $225 TO $255
- Price Increase Announcement: Needham raises the target price for AXSOME Therapeutics from $225 to $255.
- Market Implications: The adjustment reflects a positive outlook on the company's performance and potential growth in the market.
See More
Axsome Therapeutics Sees Significant Sales Growth
- Rapid Sales Growth: Axsome Therapeutics' Auvelity antidepressant has seen a 66% sales increase since its late 2022 launch, accounting for nearly 80% of the company's revenue, indicating strong market demand in CNS disorder treatments.
- FDA Approval: The FDA's approval of Auvelity for treating agitation associated with Alzheimer's disease led to a 22.9% stock surge in April, reflecting strong market confidence in its potential.
- Analyst Price Target Increases: Needham & Company raised Axsome's price target from $225 to $255, while TD Cowen increased its target from $215 to $255, suggesting a potential 23.5% upside, further boosting investor optimism.
- Significant Market Opportunity: As the first non-antipsychotic medication approved for Alzheimer's agitation, Auvelity presents a market opportunity estimated between $1 billion and $2 billion, likely enhancing Axsome's market share in this area.
See More
Axsome Therapeutics to Announce Q1 Earnings on May 4th
- Earnings Announcement: Axsome Therapeutics (AXSM) is set to announce its Q1 2023 earnings on May 4th before market open, with a consensus EPS estimate of -$0.83, reflecting a 32% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Growth Expectations: Analysts project revenue to reach $190.54 million, representing a 56.8% year-over-year increase, suggesting strong market demand and sales performance that could positively impact the stock price.
- Performance Beat Record: Over the past year, AXSM has beaten EPS estimates 25% of the time and revenue estimates 100% of the time, demonstrating stability in financial performance and bolstering market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw no upward revisions and three downward adjustments, while revenue estimates experienced seven upward revisions and four downward, reflecting mixed market sentiment regarding Axsome's future performance, which may influence investor decisions.
See More
FDA Approves Axsome's Auvelity for Alzheimer's Agitation
- New Indication Approval: The FDA has approved Axsome's Auvelity for the treatment of agitation in Alzheimer's patients, based on successful Phase 3 clinical trial data, marking a significant expansion of the drug's indications and expected to generate new revenue streams for the company.
- Large Market Potential: The treatment market for Alzheimer's agitation is substantial, and the approval of Auvelity allows it to enter this rapidly growing sector, addressing the increasing patient demand and enhancing Axsome's competitiveness in the mental health pharmaceuticals market.
- Clinical Data Support: Phase 3 clinical trials demonstrated Auvelity's effectiveness in alleviating agitation symptoms in Alzheimer's patients, further solidifying its position as a treatment option and potentially increasing physician prescribing willingness.
- Strategic Expansion Plan: This approval aligns with Axsome's strategic goals to diversify its product line and enhance market share, with expectations to accelerate growth in the neuropsychiatric drug sector.
See More
GameStop Proposes $55.5 Billion eBay Acquisition, Shares Surge
- Acquisition Proposal Surge: GameStop's unsolicited offer to acquire eBay for approximately $55.5 billion has led to a nearly 9% premarket surge in eBay's shares, indicating strong market enthusiasm for a potential merger that could create a formidable competitor to Amazon.
- Setbacks and Expectations Gap: Norwegian Cruise Line reported first-quarter earnings of 23 cents per share and $2.33 billion in revenue, both falling short of analyst expectations, resulting in a 5.5% drop in stock price, reflecting operational challenges amid rising fuel costs.
- Photonics Technology Outlook: Shares of Lumentum and Coherent rose by 3% after Rothschild & Co Redburn initiated buy ratings on both companies, with expectations that the demand for optical content in AI data center networking will drive their stock prices higher.
- Strong Food Sector Performance: Tyson Foods saw its shares rise over 2.5% after reporting better-than-expected fiscal second-quarter results, with adjusted earnings of 87 cents per share and revenue of $13.65 billion, demonstrating the company's resilience in a competitive market.
See More
Axsome Therapeutics Q1 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Performance: Axsome Therapeutics reported a Q1 GAAP EPS of -$1.26, missing expectations by $0.36, indicating ongoing challenges in achieving profitability.
- Revenue Growth: The total net product revenue for Q1 reached $191.2 million, reflecting a 57.4% year-over-year increase and exceeding expectations by $0.51 million, showcasing strong market demand.
- AUVELITY Sales: AUVELITY generated net product revenue of $153.2 million, representing a 59% year-over-year growth, indicating increasing market acceptance for treating agitation associated with Alzheimer's disease.
- Cash Flow Outlook: Axsome believes its current cash is sufficient to fund operations until reaching cash flow positivity, demonstrating confidence in its future financial health.
See More
AXSOME THERAPEUTICS INC: NEEDHAM INCREASES TARGET PRICE FROM $225 TO $255
- Price Increase Announcement: Needham raises the target price for AXSOME Therapeutics from $225 to $255.
- Market Implications: The adjustment reflects a positive outlook on the company's performance and potential growth in the market.
See More
Axsome Therapeutics Sees Significant Sales Growth
- Rapid Sales Growth: Axsome Therapeutics' Auvelity antidepressant has seen a 66% sales increase since its late 2022 launch, accounting for nearly 80% of the company's revenue, indicating strong market demand in CNS disorder treatments.
- FDA Approval: The FDA's approval of Auvelity for treating agitation associated with Alzheimer's disease led to a 22.9% stock surge in April, reflecting strong market confidence in its potential.
- Analyst Price Target Increases: Needham & Company raised Axsome's price target from $225 to $255, while TD Cowen increased its target from $215 to $255, suggesting a potential 23.5% upside, further boosting investor optimism.
- Significant Market Opportunity: As the first non-antipsychotic medication approved for Alzheimer's agitation, Auvelity presents a market opportunity estimated between $1 billion and $2 billion, likely enhancing Axsome's market share in this area.
See More
Axsome Therapeutics to Announce Q1 Earnings on May 4th
- Earnings Announcement: Axsome Therapeutics (AXSM) is set to announce its Q1 2023 earnings on May 4th before market open, with a consensus EPS estimate of -$0.83, reflecting a 32% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Growth Expectations: Analysts project revenue to reach $190.54 million, representing a 56.8% year-over-year increase, suggesting strong market demand and sales performance that could positively impact the stock price.
- Performance Beat Record: Over the past year, AXSM has beaten EPS estimates 25% of the time and revenue estimates 100% of the time, demonstrating stability in financial performance and bolstering market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw no upward revisions and three downward adjustments, while revenue estimates experienced seven upward revisions and four downward, reflecting mixed market sentiment regarding Axsome's future performance, which may influence investor decisions.
See More
FDA Approves Axsome's Auvelity for Alzheimer's Agitation
- New Indication Approval: The FDA has approved Axsome's Auvelity for the treatment of agitation in Alzheimer's patients, based on successful Phase 3 clinical trial data, marking a significant expansion of the drug's indications and expected to generate new revenue streams for the company.
- Large Market Potential: The treatment market for Alzheimer's agitation is substantial, and the approval of Auvelity allows it to enter this rapidly growing sector, addressing the increasing patient demand and enhancing Axsome's competitiveness in the mental health pharmaceuticals market.
- Clinical Data Support: Phase 3 clinical trials demonstrated Auvelity's effectiveness in alleviating agitation symptoms in Alzheimer's patients, further solidifying its position as a treatment option and potentially increasing physician prescribing willingness.
- Strategic Expansion Plan: This approval aligns with Axsome's strategic goals to diversify its product line and enhance market share, with expectations to accelerate growth in the neuropsychiatric drug sector.
See More
